|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/56 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07K 16/24 | (2006.01) |
| (11) | Number of the document | 3448391 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17790401.8 |
| Date of filing the European patent application | 2017-04-27 | |
| (97) | Date of publication of the European application | 2019-03-06 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-29 |
| (46) | Date of publication of the claims translation | 2024-06-25 |
| (86) | Number | PCT/US2017/029768 |
| Date | 2017-04-27 |
| (87) | Number | WO 2017/189805 |
| Date | 2017-11-02 |
| (30) | Number | Date | Country code |
| 201662328539 P | 2016-04-27 | US |
| (72) |
TIMONY, Gregg , US
GUJRATHI, Sheila , US
PEACH, Robert , US
OLSON, Allan , US
|
| (73) |
AbbVie Manufacturing Management Unlimited Company ,
70 Sir John Rogerson's Quay, Dublin, 2,
IE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Ligų, kurių atveju IL-13 aktyvumas yra žalingas, gydymo būdas, panaudojant anti-IL-13 antikūnus |
| METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES |
| Payment date | Validity (years) | Amount | |
| 2025-03-21 | 9 | 208.00 EUR |
| 2026-04-27 |